Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 295.11 Billion KRW | 4.63% |
| 2022 | 282.04 Billion KRW | 2.84% |
| 2021 | 274.25 Billion KRW | 6.42% |
| 2020 | 257.7 Billion KRW | -0.37% |
| 2019 | 258.66 Billion KRW | 7.07% |
| 2018 | 241.59 Billion KRW | -2.23% |
| 2017 | 247.1 Billion KRW | -0.24% |
| 2016 | 247.71 Billion KRW | 6.48% |
| 2015 | 232.64 Billion KRW | 19.9% |
| 2014 | 194.03 Billion KRW | 13.85% |
| 2013 | 170.43 Billion KRW | 25.67% |
| 2012 | 135.61 Billion KRW | -0.8% |
| 2011 | 136.7 Billion KRW | 8.12% |
| 2010 | 126.43 Billion KRW | 5.39% |
| 2009 | 119.97 Billion KRW | -0.48% |
| 2008 | 120.55 Billion KRW | 9.44% |
| 2007 | 110.15 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 73.74 Billion KRW | -4.91% |
| 2024 Q1 | 78.45 Billion KRW | 10.9% |
| 2023 FY | 295.11 Billion KRW | 4.63% |
| 2023 Q4 | 70.74 Billion KRW | -8.94% |
| 2023 Q3 | 77.69 Billion KRW | 0.8% |
| 2023 Q2 | 77.07 Billion KRW | 5.42% |
| 2023 Q1 | 73.11 Billion KRW | -1.78% |
| 2022 Q1 | 61.93 Billion KRW | -14.18% |
| 2022 Q2 | 70.71 Billion KRW | 14.17% |
| 2022 FY | 282.04 Billion KRW | 2.84% |
| 2022 Q3 | 74.96 Billion KRW | 6.02% |
| 2022 Q4 | 74.43 Billion KRW | -0.71% |
| 2021 Q3 | 73.26 Billion KRW | 8.36% |
| 2021 Q1 | 61.2 Billion KRW | 0.9% |
| 2021 Q2 | 67.61 Billion KRW | 10.46% |
| 2021 FY | 274.25 Billion KRW | 6.42% |
| 2021 Q4 | 72.17 Billion KRW | -1.49% |
| 2020 Q2 | 68.91 Billion KRW | 12.92% |
| 2020 Q3 | 67.1 Billion KRW | -2.62% |
| 2020 Q1 | 61.02 Billion KRW | -4.58% |
| 2020 FY | 257.7 Billion KRW | -0.37% |
| 2020 Q4 | 60.66 Billion KRW | -9.6% |
| 2019 Q1 | 60.55 Billion KRW | 5.4% |
| 2019 Q3 | 65.91 Billion KRW | -3.41% |
| 2019 FY | 258.66 Billion KRW | 7.07% |
| 2019 Q4 | 63.95 Billion KRW | -2.98% |
| 2019 Q2 | 68.24 Billion KRW | 12.7% |
| 2018 Q2 | 61.47 Billion KRW | 6.29% |
| 2018 Q3 | 64.83 Billion KRW | 5.47% |
| 2018 Q4 | 57.45 Billion KRW | -11.39% |
| 2018 FY | 241.59 Billion KRW | -2.23% |
| 2018 Q1 | 57.83 Billion KRW | 1.3% |
| 2017 Q1 | 57.72 Billion KRW | -0.85% |
| 2017 Q4 | 57.09 Billion KRW | -13.86% |
| 2017 Q3 | 66.28 Billion KRW | 0.42% |
| 2017 FY | 247.1 Billion KRW | -0.24% |
| 2017 Q2 | 66 Billion KRW | 14.35% |
| 2016 Q2 | 68.41 Billion KRW | 26.42% |
| 2016 Q3 | 66.95 Billion KRW | -2.13% |
| 2016 Q4 | 58.21 Billion KRW | -13.05% |
| 2016 FY | 247.71 Billion KRW | 6.48% |
| 2016 Q1 | 54.11 Billion KRW | -4.8% |
| 2015 Q4 | 56.84 Billion KRW | -13.27% |
| 2015 FY | 232.64 Billion KRW | 19.9% |
| 2015 Q3 | 65.53 Billion KRW | 3.12% |
| 2015 Q2 | 63.55 Billion KRW | 36.06% |
| 2015 Q1 | 46.7 Billion KRW | -2.05% |
| 2014 Q3 | 53.83 Billion KRW | 3.7% |
| 2014 Q2 | 51.91 Billion KRW | 27.9% |
| 2014 FY | 194.03 Billion KRW | 13.85% |
| 2014 Q1 | 40.59 Billion KRW | -3.39% |
| 2014 Q4 | 47.68 Billion KRW | -11.43% |
| 2013 Q3 | 48.37 Billion KRW | 8.26% |
| 2013 Q4 | 42.01 Billion KRW | -13.15% |
| 2013 FY | 170.43 Billion KRW | 25.67% |
| 2013 Q1 | 35.35 Billion KRW | 9.97% |
| 2013 Q2 | 44.68 Billion KRW | 26.39% |
| 2012 Q2 | 35.95 Billion KRW | 19.82% |
| 2012 Q3 | 36.47 Billion KRW | 1.45% |
| 2012 Q4 | 32.14 Billion KRW | -11.87% |
| 2012 FY | 135.61 Billion KRW | -0.8% |
| 2012 Q1 | 30 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 35.8 Billion KRW | 20.83% |
| 2011 Q3 | 36.77 Billion KRW | 2.69% |
| 2011 Q1 | 29.63 Billion KRW | -4.38% |
| 2011 FY | 136.7 Billion KRW | 8.12% |
| 2010 Q3 | 33.93 Billion KRW | -1.4% |
| 2010 Q2 | 34.42 Billion KRW | 27.12% |
| 2010 Q1 | 27.07 Billion KRW | -4.04% |
| 2010 Q4 | 30.99 Billion KRW | -8.67% |
| 2010 FY | 126.43 Billion KRW | 5.39% |
| 2009 FY | 119.97 Billion KRW | -0.48% |
| 2009 Q4 | 28.21 Billion KRW | -15.69% |
| 2009 Q3 | 33.46 Billion KRW | 5.8% |
| 2009 Q1 | 26.65 Billion KRW | -9.39% |
| 2009 Q2 | 31.63 Billion KRW | 18.71% |
| 2008 Q3 | 34.1 Billion KRW | 8.62% |
| 2008 Q2 | 31.39 Billion KRW | 22.41% |
| 2008 FY | 120.55 Billion KRW | 9.44% |
| 2008 Q4 | 29.41 Billion KRW | -13.75% |
| 2008 Q1 | 25.64 Billion KRW | -6.41% |
| 2007 Q4 | 27.4 Billion KRW | -13.21% |
| 2007 Q2 | 30.1 Billion KRW | 42.4% |
| 2007 Q1 | 21.14 Billion KRW | 0.0% |
| 2007 FY | 110.15 Billion KRW | 0.0% |
| 2007 Q3 | 31.57 Billion KRW | 4.89% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -534.594% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 18.948% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -48.385% |
| HANDOK Inc. | 151.36 Billion KRW | -94.969% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -339.004% |
| Yuhan Corporation | 564.5 Billion KRW | 47.721% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 8.409% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -1142.757% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 64.693% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -293.284% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -48.329% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -626.006% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -212.244% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -109.518% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -534.594% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -750.099% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -284.177% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 2550.008% |
| JW Holdings Corporation | 446.15 Billion KRW | 33.853% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -42.199% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 54.967% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 12.081% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -275.374% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -292.246% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -308.686% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -60.552% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -534.594% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 56.699% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 12.081% |
| Yuhan Corporation | 564.5 Billion KRW | 47.721% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -46.227% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -316.017% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -198.018% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 12.081% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -102.286% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -70.109% |
| CKD Bio Corp. | 5.01 Billion KRW | -5790.233% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -16.082% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -60.282% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -200.756% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -275.374% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 20.56% |
| Boryung Corporation | 333.26 Billion KRW | 11.447% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -489.7% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -48.329% |
| JW Lifescience Corporation | 51.32 Billion KRW | -475.0% |